The oral bioavailability of a pleuromutilin antibiotic candidate is increased after co-administration with the CYP3A4 inhibitor ritonavir and the P-gp inhibitor zosuquidar formulated as amorphous solid dispersions
2025 · International Journal of Pharmaceutics · 0 citations
https://doi.org/10.1016/j.ijpharm.2025.125397